Arrowhead Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Arrowhead Pharmaceuticals, Inc.‘s stocks are currently a part of 295 hedge funds’ portfolios, which represents 65.16% of the total amount of its stocks outstanding. This makes up a total of 68.11M shares of Arrowhead Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -0.08% or -51.65K shares fewer. As for the holding position changes, 38.31% (113) of current hedge fund investors increased the number of shares held, 33.22% (98) of current holders sold a part of the shares held, and 13.9% (41) closed the holdings completely. 38 hedge funds are new holders of Arrowhead Pharmaceuticals, Inc. stock in Q1 2022, it is 12.88% of total holders.
Hedge funds holding Arrowhead Pharmaceuticals (Q2 2017 – Q1 2022)
| Q2 2017 | 54 |
|---|---|
| Q3 2017 | 54 |
| Q4 2017 | 74 |
| Q1 2018 | 88 |
| Q2 2018 | 114 |
| Q3 2018 | 129 |
| Q4 2018 | 156 |
| Q1 2019 | 174 |
| Q2 2019 | 208 |
| Q3 2019 | 218 |
| Q4 2019 | 288 |
| Q1 2020 | 236 |
| Q2 2020 | 245 |
| Q3 2020 | 259 |
| Q4 2020 | 304 |
| Q1 2021 | 284 |
| Q2 2021 | 309 |
| Q3 2021 | 287 |
| Q4 2021 | 304 |
| Q1 2022 | 295 |
Hedge funds changes in Arrowhead Pharmaceuticals positions (Q2 2017 – Q1 2022)
| Q2 2017 | 11 | 15 | 16 | 31 | -19 |
|---|---|---|---|---|---|
| Q3 2017 | 12 | 12 | 18 | 11 | 1 |
| Q4 2017 | 27 | 22 | 14 | 7 | 4 |
| Q1 2018 | 35 | 24 | 15 | 19 | -5 |
| Q2 2018 | 48 | 30 | 24 | 21 | -9 |
| Q3 2018 | 34 | 49 | 29 | 19 | -2 |
| Q4 2018 | 55 | 45 | 40 | 26 | -10 |
| Q1 2019 | 36 | 53 | 59 | 19 | 7 |
| Q2 2019 | 61 | 75 | 50 | 24 | -2 |
| Q3 2019 | 41 | 87 | 63 | 31 | -4 |
| Q4 2019 | 94 | 81 | 87 | 17 | 9 |
| Q1 2020 | 34 | 85 | 87 | 83 | -53 |
| Q2 2020 | 40 | 94 | 75 | 31 | 5 |
| Q3 2020 | 40 | 79 | 96 | 23 | 21 |
| Q4 2020 | 69 | 91 | 110 | 25 | 9 |
| Q1 2021 | 31 | 81 | 124 | 47 | 1 |
| Q2 2021 | 54 | 97 | 106 | 27 | 25 |
| Q3 2021 | 33 | 108 | 102 | 50 | -6 |
| Q4 2021 | 51 | 102 | 109 | 34 | 8 |
| Q1 2022 | 38 | 113 | 98 | 41 | 5 |
Hedge funds changes in Arrowhead Pharmaceuticals stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 71,000 | 284,000 |
|---|---|---|
| Q3 2017 | 2,653,000 | 879,000 |
| Q4 2017 | 2,014,000 | 893,000 |
| Q1 2018 | 2,290,000 | 2,491,000 |
| Q2 2018 | 12,820,000 | 8,116,000 |
| Q3 2018 | 27,210,000 | 24,451,000 |
| Q4 2018 | 6,111,000 | 8,791,000 |
| Q1 2019 | 11,158,000 | 12,268,000 |
| Q2 2019 | 32,400,000 | 23,143,000 |
| Q3 2019 | 20,191,000 | 33,697,000 |
| Q4 2019 | 90,946,000 | 93,666,000 |
| Q1 2020 | 26,514,000 | 24,715,000 |
| Q2 2020 | 56,721,000 | 35,635,000 |
| Q3 2020 | 51,877,000 | 31,660,000 |
| Q4 2020 | 132,899,000 | 64,440,000 |
| Q1 2021 | 58,993,000 | 26,126,000 |
| Q2 2021 | 94,957,000 | 44,875,000 |
| Q3 2021 | 61,149,000 | 36,478,000 |
| Q4 2021 | 72,850,000 | 37,534,000 |
| Q1 2022 | 121,458,000 | 25,137,000 |